DuPont de Nemours Earnings Call Transcripts
Fiscal Year 2026
-
First quarter 2026 results exceeded expectations with strong sales, margin expansion, and double-digit EPS growth. Guidance for the full year was raised, reflecting robust performance in healthcare, aerospace, and operational execution, while pricing actions offset input cost pressures.
Fiscal Year 2025
-
Fourth quarter and full-year 2025 results exceeded guidance, with strong margin and EPS growth driven by operational discipline and portfolio transformation. 2026 guidance calls for 3% organic sales growth, margin expansion, and robust free cash flow, with Healthcare and Water segments leading growth.
-
Q3 saw 6% organic sales and EBITDA growth, with strong performance in healthcare, water, and electronics. Full-year guidance was raised, a $2B buyback and $0.20 dividend were announced, and the CUNY separation was completed, strengthening the balance sheet and focus on core growth areas.
-
A streamlined portfolio now focuses on healthcare, water, and diversified industrials, targeting 3–4% organic revenue growth and 8–10% EPS CAGR by 2028. Operational excellence, disciplined capital allocation, and innovation drive margin expansion and shareholder value, with M&A and portfolio optimization supporting further growth.
-
Second quarter saw 2% organic sales growth and 8% higher operating EBITDA, led by electronics and healthcare/water, while construction remained weak. Full-year earnings guidance was raised, a $177M environmental settlement was announced, and the Cunity spinoff remains on track for November 1.
-
The meeting covered strong 2024 financial results, progress on the Qnity spin-off, and strategic focus on growth markets. All management proposals, including director elections and auditor ratification, were approved. Key governance and executive compensation topics were addressed.
-
First-quarter results exceeded expectations with strong growth in electronics, healthcare, and water, driving a 16% year-over-year increase in operating EBITDA and a 30% rise in adjusted EPS. The electronics spinoff (Qnity) remains on track, and tariff mitigation actions are expected to limit 2025 net cost impact to $60 million.
Fiscal Year 2024
-
Q4 sales rose 7% year-over-year, with strong growth in electronics, water, and healthcare. 2025 guidance calls for mid-single-digit organic growth, continued margin strength, and the electronics spinoff by November 1. AI-related sales surged 30% in 2024.
-
Q3 2024 saw strong year-over-year growth in sales, EBITDA, and EPS, driven by volume recovery and operational excellence. Guidance for 2024 was raised, with continued momentum expected in electronics and water, and progress on business separations.
-
Second quarter results surpassed guidance with strong electronics recovery, margin expansion, and robust cash flow. Full-year guidance was raised, reflecting ongoing recovery, AI-driven growth, and the Donatelle acquisition. PFAS litigation risk is declining, and segment performance is improving.